A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol

Clinical Therapeutics

Volumn 24, Issue 12, 2002, Pages 2077-2087

  Shapiro, Gail S ^a   Yegen, Ümit ^b   Xiang, Jim ^b   Kottakis, John ^c   Cioppa, Giovanni Della ^c  

^a ASTHMA Inc Clinical Research Center   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Aerolizer; Albuterol; Asthma.; Exercise induced bronchoconstriction; Formoterol; Inhaler

Indexed keywords

FORMOTEROL; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PEAK EXPIRATORY FLOW; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

EID: 0036922555     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80098-4     Document Type: Article

References (16)

1. Anderson SD. Issues in exercise-induced asthma. J Allergy Clin Immunol. 1985;76:763-772.
2. Global initiative for asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. Rev Ed. Bethesda, Md: National Institutes of Health; 2002.
3. Tilles SA, Nelson HS. Long-acting inhaled beta agonists. J Asthma. 1995;32:397-404.
4. Busse WW. Long- and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma. Arch Intern Med. 1996;156:1514-1520.
5. Guill M. Exercise-induced bronchospasm in children: Effects and therapies. Pediatr Ann. 1996;25:146-149, 153.
6. Wegener T, Hedenstrom H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest. 1992;102:535-538.
7. van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. Eur Respir J. 1996;9:1684-1688.
8. Boner AL, Spezia E, Piovesan P, et al. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med. 1994;149:935-939.
9. Quebe-Fehling E, Brambilla R, Bromly CL, et al. The duration of action of inhaled formoterol dry powder. Br J Clin Pract. 1996;50:446-449.
10. Serevent Diskus [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
11. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127:725-734.
12. Bar-Yishay E, Ben-Dov I, Godfrey S. Refractory period after hyperventilation-induced asthma. Am Rev Respir Dis. 1983;127:572-574.
13. Schaanning J, Vilsvik J, Henriksen AH, Bratten G. Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol. 1996;76:57-60.
14. McAlpine LG, Thomson NC. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist. Respir Med. 1990;84:293-295.
15. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol. 1992;89:1176-1182.
16. Tsoy AN, Cheltzov VV, Zaseyeva OV, et al. Preventive effect of formoterol aerosol in exercise-induced bronchoconstriction. Eur Respir J. 1990;3:235S. Abstract.